Genmab — Januar 2021
-
Hvis de 100 ledige stillinger følger gennemsnittet for resten af staben, bliver det 120 mio i øget lønninger. Til gengæld vil de gns. bidrage med 10 mio i omsætning pr. hoved og dermed et dækningsbidraget på 9 mio. pr. mand. Ansæt venligst nogle flere
-
pr. 31. december 2019 var der ansat 550 fuldtid, så det er en pæn %-
forøgelse -
Grov tommelfinger regel siger at hver ny FTer koster 1 mio.
-
Den biks jeg arbejder i har også godt 100 stillinger slået op. Men på årsbasis forventes der godt 400 nye. Har man 100 slået op nu, så kommer der mange flere til i løbet af året
-
altså nye FTEer. Dertil genbesættelser
-
Så 2021 kunne godt blive året hvor genmab runder 1000 personer
-
-
-
God morgen
-
God morgen.
-
Amivantamab presentation
https://www.oncologysciencehub.com/wclc2020/ -
thx EL - nice looking ORR and counting stable disease very impressive indeed
-
"Sabari was confident enough in amivantamab’s data to take a swipe at mobocertinib, saying the Takeda program matched up poorly on safety given Thursday’s results" https://endpts.com/jj-pushes-new-amivantamab-data-for-nsclc-subset-trying-to-bolster-case-for-quick-fda-approval/
-
comments from Joshua Bauml, MD
@Jbauml
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind